Patients who recover from CIRS (via remediation and treatment) remain genetically susceptible (HLA type does not change); they retain vulnerability to reactivation if reexposed to water-damaged buildings. However, if MSH levels rise to normal during treatment, some individuals may gain functional resistance. Those who travel extensively or cannot guarantee mold-free environments should take prophylactic medications continuously (e.g., low-dose VIP, which has essentially zero side effects).